Alexithymia in Patients With Substance Use Disorders and Its Relationship With Psychiatric Comorbidities and Health-Related Quality of Life

Other authors

Institut Català de la Salut

[Palma-Álvarez RF, Ros-Cucurull E, Daigre C, Ramos-Quiroga JA, Grau-López L] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Bellaterra, Spain. Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain. [Perea-Ortueta M] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Serrano-Pérez P] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Bellaterra, Spain. Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Martínez-Luna N, Salas-Martínez A] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-06-15T12:34:35Z

2021-06-15T12:34:35Z

2021-04-09

Abstract

Alexitimia; Qualitat de vida relacionada amb la salut; Trastorn per consum de substàncies


Alexitimia; Calidad de vida relacionada con la salud; Trastorno por uso de sustancias


Alexithymia; Health-related quality of life; Substance use disorder


Background: Alexithymia frequently correlates with several psychiatric disorders, including substance use disorder (SUD). However, most studies reporting the associations between alexithymia and psychiatric disorders have been performed in populations without SUD. This research, therefore, evaluates alexithymia in Spanish patients with SUD and the relationship among alexithymia, psychiatric comorbidities, psychological symptoms/traits, SUD variables, and health-related quality of life (HRQoL). Methodology: A cross-sectional study was conducted with 126 Spanish outpatients with SUD (75.4% males; mean age 43.72 ± 14.61 years), correlating their alexithymia levels (using the Toronto Alexithymia Scale 20 [TAS-20]) to their psychiatric comorbidities, psychological symptoms/traits, SUD variables, and HRQoL. Results: Alexithymia was significantly higher in patients who had cannabis use disorder. Higher alexithymia scores were also related to higher levels of depression, anxiety, impulsivity, and lower HRQoL. After multivariate analysis, trait anxiety, impulsivity, and the physical component summary of the HRQoL were found to be independently related to alexithymia. Conclusions: SUD patients with higher alexithymia levels have more frequently psychiatric comorbidities, present specific psychological features, and have worse HRQoL. Hence, it is important to evaluate these factors and offer more accurate psychotherapeutic approaches for this patient population.

Document Type

Article


Published version

Language

English

Publisher

Frontiers Media

Related items

Frontiers in Psychiatry;12

https://www.frontiersin.org/articles/10.3389/fpsyt.2021.659063/full

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)